100448-53-1

Basic information

• Product Name: 2-Benzyl-7-chloro-1-oxo-1,2-dihydro-phthalazine-6-sulfonyl chloride
• Synonyms: 2-Benzyl-7-chloro-1-oxo-1,2-dihydro-phthalazine-6-sulfonyl chloride
• CAS NO: 100448-53-1
• Molecular Weight: 369.228
• Mol File: 100448-53-1.mol
• Article Data: 1

Chemical Properties

• CAS DataBase Reference: 2-Benzyl-7-chloro-1-oxo-1,2-dihydro-phthalazine-6-sulfonyl chloride(CAS DataBase Reference)
• NIST Chemistry Reference: 2-Benzyl-7-chloro-1-oxo-1,2-dihydro-phthalazine-6-sulfonyl chloride(100448-53-1)
• EPA Substance Registry System: 2-Benzyl-7-chloro-1-oxo-1,2-dihydro-phthalazine-6-sulfonyl chloride(100448-53-1)

Safety Data

• Hazardous Substances Data: 100448-53-1(Hazardous Substances Data)

Upstream product

• 100448-46-2 5-amino-6-chloro-3-hydroxyphthalimidine 
• 5566-48-3 5-amino-6-chloroisoindoline-1,3-dione 
• 89-20-3 4-chlorophthalic acid 
• 50-84-0 2,4 dichlorobenzoic acid 
• 6015-57-2 5-chloro-6-nitroisoindole-1,3-dione 
• 7147-90-2 4-chlorophthalimide 
• 100448-49-5 6-amino-2-benzyl-7-chloro-1(2H)-phthalazinone 

Downstream Products

• 100448-43-9 2-Benzyl-7-chloro-1-oxo-1,2,3,4-tetrahydro-phthalazine-6-sulfonic acid amide 
• 100448-33-7 2-Benzyl-7-chloro-1-oxo-1,2-dihydro-phthalazine-6-sulfonic acid amide 

Relevant articles and documents

Synthesis, Saludiuretic, and Antihypertensive Activity of 6,7-Disubstituted 1(2H)- and 3,4-Dihydro-1(2H)-phthalazinones

The synthesis of the isomeric series 6-chloro-7-sulfamoyl-and 7-chloro-6-sulfamoyl-1(2H)-phthalazinones (1 and 2) and 6-chloro-7-sulfamoyl- and 7-chloro-6-sulfamoyl-3,4-dihydro-1(2H)-phthalazinones (3 and 4), combining structural features characteristic to furosemide and hydralazine, is described, the mechanism of the formation of 1 and 2 is discussed, and their structure-activities relationships are studied.Preliminary screening in the rat shows that series 1 and 3 exhibit diuretic and saluretic activity similar to that of chlorothiazide with, however, Na+/K+ ratios more favorable than chlorothiazide and furosemide.The compounds of series 2 and 4 are practically inactive.All four series show initial antihypertensive activity lower than that of hydralazine.However, compounds 1a, 1c, and 4a show a higher activity at 8 and/ or 24 h after administration and thus may offer a unique combination of a "loop" diuresis with direct long-acting peripheral vasodilating effects.